ALK and non-small cell lung carcinoma: Nonetheless, a rapidly growing understanding of NSCLC has led to the approval of several inhibitors against driving mutated proteins, such as the EGFR family (ERBB-1, ERBB-2), ALK, ROS1, MET, RET, NTRK, and RAF [178].